Download PDF
Klinische Neurophysiologie 2008; 39(4): 208-218
DOI: 10.1055/s-2008-1067555
Fort- und Weiterbildung

© Georg Thieme Verlag KG Stuttgart · New York

Lambert-Eaton-Syndrom – Aktuelles zu Diagnose und Therapie

Lambert-Eaton Myasthenic Syndrome – Recent Advances in Diagnosis and TherapyJ.  P.  Sieb, C.  Veauthier
Further Information

Publication History

Publication Date:
12 January 2009 (online)

Also available at
    Permissions and Reprints

Lernziele

Klinisches Bild des Lambert-Eaton-Syndroms als paraneoplastische bzw. idiopathische Autoimmunerkrankung Differenzierte Kenntnis der elektrophysiologischen und serologischen Diagnostik Vor- und Nachteile der therapeutischen Optionen beim Lambert-Eaton-Syndrom

Literatur

  • 1 Grommes C, Preston D C, Al Kadhimi Z. et al . Lambert-Eaton syndrome with large-cell neuroendocrine carcinoma of the lung.  Muscle Nerve. 2008;  37 786-789
    CrossrefPubMedGoogle Scholar
  • 2 Roohi F, Smith P R, Bergman M. et al . A diagnostic and management dilemma: combined paraneoplastic myasthenia gravis and Lambert-Eaton myasthenic syndrome presenting as acute respiratory failure.  Neurologist. 2006;  12 322-326
    CrossrefPubMedGoogle Scholar
  • 3 Wirtz P W, Willcox N, van der Slik A R. et al . HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome.  J Neuroimmunol. 2005;  159 230-237
    CrossrefPubMedGoogle Scholar
  • 4 Purroy G F, Comabella M, Raguer N. et al . Lambert-Eaton Myasthenic syndrome associated with sarcoidosis.  J Neurol. 2005;  252 1127-1128
    PubMedGoogle Scholar
  • 5 Truffert A, Allali G, Vokatch N. et al . Mild clinical expression of Lambert-Eaton myasthenic syndrome in a patient with HIV infection.  J Neurol Neurosurg Psychiatry. 2007;  78 910-911
    CrossrefPubMedGoogle Scholar
  • 6 Adams P J, Snutch T P. Calcium channelopathies: voltage-gated calcium channels.  Subcell Biochem. 2007;  45 215-251
    PubMedGoogle Scholar
  • 7 Wirtz P W, Sotodeh M, Nijnuis M. et al . Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome.  J Neurol Neurosurg Psychiatry. 2002;  73 766-768
    CrossrefPubMedGoogle Scholar
  • 8 Rudnicki S A. Lambert-Eaton myasthenic syndrome with pure ocular weakness.  Neurology. 2007;  68 1863-1864
    CrossrefPubMedGoogle Scholar
  • 9 Payne S, Wilkins D, Howard R. An unusual cause of dysphagia.  J Neurol Neurosurg Psychiatry. 2005;  76 146
    CrossrefPubMedGoogle Scholar
  • 10 Odabasi Z, Demirci M, Kim D S. et al . Postexercise facilitation of reflexes is not common in Lambert-Eaton myasthenic syndrome.  Neurology. 2002;  59 1085-1087
    PubMedGoogle Scholar
  • 11 Wirtz P W, Wintzen A R, Verschuuren J J. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer.  Muscle Nerve. 2005;  32 226-229
    CrossrefPubMedGoogle Scholar
  • 12 O'Neill J H, Murray N MF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome.  Brain. 1988;  111 577-596
    PubMedGoogle Scholar
  • 13 Sanders D B. Lambert-eaton myasthenic syndrome: diagnosis and treatment.  Ann N Y Acad Sci. 2003;  998 500-508
    CrossrefPubMedGoogle Scholar
  • 14 Maddison P, Newsom-Davis J, Mills K R. et al . Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma.  Lancet. 1999;  353 117-118
    PubMedGoogle Scholar
  • 15 Wirtz P W, Lang B, Graus F. et al . P / Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer.  J Neuroimmunol. 2005;  164 161-165
    CrossrefPubMedGoogle Scholar
  • 16 Elrington G M, Murray N M, Spiro S G. et al . Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients.  J Neurol Neurosurg Psychiatry. 1991;  54 764-767
    CrossrefPubMedGoogle Scholar
  • 17 Wirtz P W, van Dijk J G, van Doorn P A. et al . The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands.  Neurology. 2004;  63 397-398
    PubMedGoogle Scholar
  • 18 Sieb J P, Dengler R, Jerusalem F. Das nichtparaneoplastische Lambert-Eaton-Syndrom. Eine häufig übersehene Diagnose?.  Nervenarzt. 1992;  63 234-239
    PubMedGoogle Scholar
  • 19 Shapiro B E, Preston D C. Repetitive nerve stimulation and exercise testing.  Phys Med Rehabil Clin N Am. 2003;  14 185-206
    PubMedGoogle Scholar
  • 20 Tim R W, Massey J M, Sanders D B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment.  Neurology. 2000;  54 2176-2178
    PubMedGoogle Scholar
  • 21 Hatanaka Y, Oh S J. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome.  Muscle Nerve. 2008;  37 572-575
    CrossrefPubMedGoogle Scholar
  • 22 Oh S J, Kurokawa K, Claussen G C. et al . Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome.  Muscle Nerve. 2005;  32 515-520
    CrossrefPubMedGoogle Scholar
  • 23 Oh S J, Hatanaka Y, Claussen G C. et al . Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome.  Muscle Nerve. 2007;  35 178-183
    CrossrefPubMedGoogle Scholar
  • 24 Baslo M B, Deymeer F, Serdaroglu P. et al . Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis.  Neuromuscul Disord. 2006;  16 454-458
    CrossrefPubMedGoogle Scholar
  • 25 Meriggioli M N, Sanders D B. Advances in the diagnosis of neuromuscular junction disorders.  Am J Phys Med Rehabil. 2005;  84 627-638
    CrossrefPubMedGoogle Scholar
  • 26 Sanders D B. The effect of firing rate on neuromuscular jitter in Lambert-Eaton myasthenic syndrome.  Muscle Nerve. 1992;  15 256-258
    PubMedGoogle Scholar
  • 27 Lang B, Vincent A. Autoantibodies to ion channels at the neuromuscular junction.  Autoimmun Rev. 2003;  2 94-100
    CrossrefPubMedGoogle Scholar
  • 28 Graus F, Lang B, Pozo-Rosich P. et al . P / Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer.  Neurology. 2002;  59 764-766
    CrossrefPubMedGoogle Scholar
  • 29 Mason W P, Graus F, Lang B. et al . Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome.  Brain. 1997;  120 (Pt 8) 1279-1300
    CrossrefPubMedGoogle Scholar
  • 30 Liao Y J, Safa P, Chen Y R. et al . Anti-Ca2+ channel antibody attenuates Ca2+ currents and mimics cerebellar ataxia in vivo.  Proc Natl Acad Sci USA. 2008;  105 2705-2710
    CrossrefPubMedGoogle Scholar
  • 31 Motomura M, Lang B, Johnston I. et al . Incidence of serum anti-P / O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.  J Neurol Sci. 1997;  147 35-42
    CrossrefPubMedGoogle Scholar
  • 32 Sabater L, Titulaer M, Saiz A. et al . SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome.  Neurology. 2008;  70 924-928
    CrossrefPubMedGoogle Scholar
  • 33 Oh S J, Sher E. MG and LEMS overlap syndrome: case report with electrophysiological and immunological evidence.  Clin Neurophysiol. 2005;  116 1167-1171
    CrossrefPubMedGoogle Scholar
  • 34 Sha S J, Layzer R B. Myasthenia gravis and Lambert-Eaton myasthenic syndrome in the same patient.  Muscle Nerve. 2007;  36 115-117
    CrossrefPubMedGoogle Scholar
  • 35 Katz J S, Wolfe G I, Bryan W W. et al . Acetylcholine receptor antibodies in the Lambert-Eaton myasthenic syndrome.  Neurology. 1998;  50 470-475
    PubMedGoogle Scholar
  • 36 Lennon V A. Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome.  Neurology. 1997;  48 (Suppl. 5) 23-27
    PubMedGoogle Scholar
  • 37 Evoli A, Minicuci G M, Vitaliani R. et al . Paraneoplastic diseases associated with thymoma.  J Neurol. 2007;  254 756-762
    PubMedGoogle Scholar
  • 38 Warren N M, Bennett M, Lai M. et al . Lambert-Eaton myasthenic syndrome associated with thymitis.  Neurology. 2005;  64 168-169
    PubMedGoogle Scholar
  • 39 Verschuuren J J, Wirtz P W, Titulaer M J. et al . Available treatment options for the management of Lambert-Eaton myasthenic syndrome.  Expert Opin Pharmacother. 2006;  7 1323-1336
    CrossrefPubMedGoogle Scholar
  • 40 Oh S J, Kim D S, Head T C. et al . Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.  Muscle Nerve. 1997;  20 1146-1152
    CrossrefPubMedGoogle Scholar
  • 41 Lundh H, Nilsson O, Rosén I. 4-Aminopyridine – a new drug tested in the treatment of Eaton-Lambert syndrome.  J Neurol Neurosurg Psychiatry. 1977;  40 1109-1112
    CrossrefPubMedGoogle Scholar
  • 42 Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome.  Cochrane Database Syst Rev. 2005;  , CD003279
    PubMedGoogle Scholar
  • 43 Sanders D B, Massey J M, Sanders L L. et al . A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome.  Neurology. 2000;  54 603-607
    CrossrefPubMedGoogle Scholar
  • 44 McEvoy K M, Windebank A J, Daube R. et al . 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.  N Engl J Med. 1989;  321 1567-1571
    CrossrefPubMedGoogle Scholar
  • 45 Buchwald B, Ahangari R, Weishaupt A. et al . Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins.  Muscle Nerve. 2005;  31 487-494
    CrossrefPubMedGoogle Scholar
  • 46 Bui P K, Kuczkowski K M, Moeller-Bertram T. et al . New onset Lambert-Eaton myasthenic syndrome as an unexpected cause of delayed recovery from general anesthesia after thyroidectomy.  Ann Fr Anesth Reanim. 2004;  23 926-927
    PubMedGoogle Scholar
  • 47 Pichler M, Wang Z, Grabner-Weiss C. et al . Block of P / Q-type calcium channels by therapeutic concentrations of aminoglycoside antibiotics.  Biochemistry. 1996;  35 14 659-14 664
    PubMedGoogle Scholar
  • 48 Schottland J R. Ofloxacin in the Lambert-Eaton myasthenic syndrome.  Neurology. 1999;  52 435
    PubMedGoogle Scholar
  • 49 Schneider-Gold C, Wessig C, Hopker M. et al . Pregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndrome.  J Neurol. 2006;  253 1236-1237
    PubMedGoogle Scholar
  • 50 Lecky B R. Transient neonatal Lambert-Eaton syndrome.  J Neurol Neurosurg Psychiatry. 2006;  77 1094
    PubMedGoogle Scholar
  • 51 Pelufo-Pellicer A, Monte-Boquet E, Roma-Sanchez E. et al . Fetal exposure to 3,4-diaminopyridine in a pregnant woman with congenital myasthenia syndrome.  Ann Pharmacother. 2006;  40 762-766
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Jörn P. Sieb

Klinik für Neurologie, Geriatrie und Palliativmedizin, HANSE-Klinikum Stralsund

Große Parower Straße 47–53

18435 Stralsund

Email: j.sieb@klinikum-hst.de

      >